Outcome

The study evaluated the impact of hyperbaric oxygen therapy (HBOT) on COVID-19 patients with respiratory distress. Administering HBOT at 2.0 atmospheres to 20 patients resulted in only 10% needing intubation and none remaining hospitalized. In contrast 30% of the 60 patients in the control group required intubation 22% died and 5% remained hospitalized.

Introduction

The COVID-19 pandemic has presented unprecedented challenges in managing respiratory distress among patients. Hyperbaric oxygen therapy (HBOT) which involves breathing pure oxygen in a pressurized environment has shown promise as a therapeutic intervention for various medical conditions. This study evaluates the efficacy and safety of HBOT for COVID-19 patients with respiratory distress. Conducted at NYU Winthrop Hospital the trial included 20 patients treated with HBOT at 2.0 atmospheres of pressure for up to five sessions. Outcomes were compared to a control group of 60 propensity-matched patients who did not receive HBOT. The results indicate that HBOT significantly reduced the rates of intubation and inpatient mortality. Specifically only 10% of HBOT-treated patients required intubation and subsequently died and none remained hospitalized. In contrast 30% of the control group required intubation 22% died and 5% remained hospitalized. Adjusted subdistribution hazard ratios demonstrated a lower risk for both inpatient mortality (0.37) and mechanical ventilation (0.26) in the HBOT group. These findings suggest that HBOT may improve survival and reduce the need for mechanical ventilation in COVID-19 patients advocating for further extensive multicenter randomized trials to validate these outcomes.

Results

The study conducted at NYU Winthrop Hospital during the spring of 2020 evaluated the efficacy and safety of hyperbaric oxygen therapy (HBOT) in COVID-19 patients experiencing respiratory distress. Twenty patients received HBOT at 2.0 atmospheres of pressure for up to five sessions each lasting 90 minutes. A control group comprising 60 propensity-matched patients did not receive HBOT.

The results were notably favorable for the HBOT group. Only 2 patients (10%) required intubation and subsequently died and none remained hospitalized at the end of the study period. In contrast the control group had significantly poorer outcomes: 18 patients (30%) required intubation 13 patients (22%) died and 3 patients (5%) still remained hospitalized including one who was still on mechanical ventilation.

The adjusted subdistribution hazard ratios provided further insight into the treatment efficacy. For the need for mechanical ventilation the hazard ratio was 0.26 with statistical significance (p=0.046) indicating a noteworthy reduction in the HBOT group. The hazard ratio for inpatient mortality was 0.37 though it did not reach statistical significance (p=0.14).

These findings indicate that HBOT may be a safe and potentially effective treatment option for reducing the necessity for mechanical ventilation in COVID-19 patients with respiratory distress. While the reduction in inpatient mortality suggested a positive trend the results did not achieve statistical significance pointing to the need for larger studies to confirm these preliminary outcomes.

In summary the study suggests significant benefits of HBOT in managing severe respiratory distress in COVID-19 patients particularly in reducing the requirement for mechanical ventilation. Further multicenter randomized controlled trials are recommended to validate these initial findings and firmly establish HBOT as a viable therapeutic option for COVID-19 induced respiratory failure.

Conclusion

In conclusion this study evaluated the impact of hyperbaric oxygen therapy (HBOT) on COVID-19 patients experiencing respiratory distress yielding promising results. HBOT administered at 2.0 atmospheres of pressure for up to five sessions was associated with a significant reduction in the need for mechanical ventilation and a lower hazard ratio for inpatient mortality compared to the control group. Specifically the HBOT group had a 10% intubation rate with no patients remaining hospitalized whereas the control group experienced a 30% intubation rate 22% mortality and a small percentage of patients still hospitalized.

These findings highlight the potential of HBOT to improve survival rates and reduce the necessity for mechanical ventilation in COVID-19 patients. This underscores the promise of HBOT as a supplementary treatment for respiratory distress associated with COVID-19. However to substantiate these preliminary findings future research through larger multicenter randomized controlled trials is essential. Such studies should aim to further elucidate the efficacy safety and potential mechanisms underlying the benefits of HBOT in severe respiratory conditions.

Overall this study contributes to the growing body of evidence supporting HBOT as a potentially valuable therapeutic intervention for COVID-19 potentially transforming clinical practices and improving patient outcomes in the management of respiratory distress.